| SFDA Approved Use |
Fulvestrant is indicated:
• as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: - not previously treated with endocrine therapy, or - with disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy. • in combination with Palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. In pre- or perimenopausal women, the combination treatment with Palbociclib should be combined with a luteinising hormone releasing hormone (LHRH) agonist |
|---|
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
Thu 13 Aug 2026
Beta version
Official Saudi government website domains end with gov.sa
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Official Reliable websites use HTTPS
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.